Table 2 Comparison of baseline and clinical characteristics between patients who shifted versus those who did not switch to NOACs during follow-up
Shift to NOACs during follow-up | |||
|---|---|---|---|
Shifted N = 3737 % (n) | Did not Shift N = 3,877 % (n) | p-value | |
Age (years), Mean (SD) | 73.5 (8.8) | 73.3 (11.2) | < 0.001 |
Median (IQR) | 69.3 (62.6; 75.6) | 68.3 (60.2; 75.7) | |
Female sex | 47.9% (1791) | 42.9% (1662) | < 0.001 |
Immigration ≥ 1990 | 39.6% (1481) | 38.5% (1494) | 0.339 |
SES score, Mean (SD) | 5.85 (1.76) | 5.90 (1.79) | 0.207 |
Median (IQR) | 6 (5; 7) | 6 (5; 7) | |
District | |||
North | 17.7% (661) | 18.9% (734) | < 0.001 |
Sharon | 17.1% (639) | 17.7% (685) | |
South | 22.1% (827) | 18.3% (708) | |
Center | 18.7% (700) | 21.0% (813) | |
Jerusalem/ Hashfela | 24.4% (910) | 24.2% (937) | |
CHADS2 score Mean (SD), | 2.29 (1.21) | 2.18 (1.36) | < 0.001 |
Median (IQR) | 2 (1; 3) | 2 (1; 3) | |
CHADS2 risk levels | |||
0 | 3.9% (146) | 9.1% (352) | < 0.001 |
1 | 22.2% (831) | 24.1% (934) | |
≥ 2 | 73.9% (2760) | 66.8% (2591) | |
CHA2DS2 VASC score Mean (SD) | 3.92 (1.59) | 3.68 (1.80) | < 0.001 |
Median (IQR) | 4 (3; 5) | 4 (2; 5) | |
Baseline comorbidity | |||
Congestive heart failure | 18.0% (672) | 23.3% (902) | < 0.001 |
Ischemic heart disease | 34.1% (1275) | 35.4% (1371) | 0.265 |
Myocardial infarction | 13.8% (516) | 14.6% (566) | 0.339 |
IHD non-MI | 23.3% (870) | 23.7% (919) | 0.683 |
Cerebrovascular accident | 13.8% (514) | 13.3% (516) | 0.593 |
Transient ischemic attack | 7.4% (276) | 6.7% (260) | 0.265 |
Peripheral arterial disease | 7.5% (279) | 8.2% (317) | 0.266 |
Chronic kidney disease | 46.3% (1732) | 43.6% (1690) | 0.017 |
Diabetes mellitus | 40.4% (1509) | 33.4% (1293) | < 0.001 |
Hyperlipidemia | 88.8% (3318) | 83.2% (3224) | < 0.001 |
Hypertension | 87.9% (3284) | 79.9% (3097) | < 0.001 |
Chronic obstructive pulmonary disease | 2.9% (110) | 3.2% (123) | 0.608 |
Medications | |||
ACE inhibitors | 35.4% (1322) | 33.2% (1287) | 0.1 |
ARBs | 52.2% (1950) | 48.3% (1871) | 0.048 |
Beta blockers | 20.3% (760) | 17.7% (685) | 0.001 |
Ca blockers | 45.6% (1703) | 44.0% (1705) | 0.003 |
Diuretic | 13.8% (515) | 11.7% (455) | 0.169 |
Nitrates | 1.0% ( 36) | 1.0% ( 37) | 0.008 |
Other antiplatelets | 4.1% (152) | 2.6% ( 99) | 0.999 |
Aspirin | 30.3% (1133) | 25.6% (993) | < 0.001 |
Incident 2012–2015 | 34.1% (1274) | 27.9% (1081) | < 0.001 |